Browsing by Keywords "Tamoxifen"
Now showing items 1-5 of 5
-
The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity
(PUBLIC LIBRARY OF SCIENCE, 2010)Background Breast cancer is a remarkably heterogeneous disease. Luminal, basal-like, "normal-like", and ERBB2+ subgroups were identified and were shown to have different prognoses. The mechanisms underlying this heterogeneity ... -
Identification of long non-coding RNAs overcoming tamoxifen resistance in estrogen receptor alpha positive breast cancer
(Bilkent University, 2017-09)Most of the breast cancer incidences all over the world fall into Estrogen Receptor alpha (ERα)-positive breast cancer subtype, which are treated with endocrine therapy. Tamoxifen, a selective ER modulator drug, is the ... -
MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer
(John Wiley and Sons Ltd, 2014)Tamoxifen is an endocrine therapy which is administered to up to 70% of all breast cancer patients with oestrogen receptor alpha (ERα) expression. Despite the initial response, most patients eventually acquire resistance ... -
The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelialmesenchymal transition in breast cancer
(Impact Journals LLC, 2016)Tumor cells develop drug resistance which leads to recurrence and distant metastasis. MicroRNAs are key regulators of tumor pathogenesis; however, little is known whether they can sensitize cells and block metastasis ... -
qPCR validation of in vivo diagnostic importance and regulation by estrogen for CHRNA5 isoform expression in breast cancer
(Bilkent University, 2014)Breast cancer has multiple molecular subtypes; normal-like, basal-like, luminal A, luminal B and HER2 positive depending on receptor status of tumor cells. Cancer therapy is tailored according to the type of cancer; hence ...
